Transplantation & Cellular Therapy
The latest news, research, and perspectives in transplantation and cellular therapy. Hematopoietic cell transplantation involves replacing unhealthy bone marrow with healthy stem cells in patients with hematologic disorders. In the growing field of non-transplant cellular therapies, including chimeric antigen receptor T-cell therapies, patient- or donor-derived cells are being explored for the treatment and potential cure of blood cancers.
Advertisement
None of the patients with DDX41 variants who received post-HSCT cyclophosphamide developed severe acute GVHD.
The overall neutrophil response rate, defined as recovery or improvement, was 84% within a median of nine days.
Dr. Pickl discusses potential future uses and implications of a novel biomarker to predict responses to CAR-T in DLBCL.
Dr. Bishop discusses the matter with host Chadi Nabhan, MD, MBA, FACP, and speaks about why CAR-T doesn't always work.
Brexucabtagene autoleucel led to “high rates of durable response” in adults with relapsed/refractory B-cell ALL.
The study's investigators identified a four-gene model that segregated patients with different survival probabilities.
Advertisement
The study used natural language processing for computer-assisted review of electronic health records.
The investigators plan to continue using the monitoring strategies and further study patient outcomes.
The multicenter, single-arm phase II trial evaluated axicabtagene ciloleucel in patients with MZL or follicular lymphoma.
The research has implications for patients with hematologic malignancies who need to undergo allogeneic HSCT.
BMS-986393, a GPRC5D-directed CAR-T, had a "favorable” safety profile with “promising” preliminary efficacy in R/R MM.
Survival outcomes are typically poor in patients with relapsed/refractory aggressive BCL who relapse after anti-CD19 CAR-T.
Post-transplant cyclophosphamide]-based GVHD prophylaxis mitigates the development of gastrointestinal GVHD.
Children with R/R B-cell ALL who received co-administered CD19-and CD22-directed CAR-T therapy had a 99% CR.
Allogeneic CAR T-cells had “encouraging safety and efficacy” in patients with CD7-positive hematologic malignancies.
Axicabtagene ciloleucel led to higher response rates and higher toxicity rates than tisagenlecleucel in R/R DLBCL.
Allogeneic off-the-shelf CAR T-cells “showed evidence of antileukemic activity” in heavily pretreated patients...
Certain genetic features in tumor and plasma samples from patients with LBCL are associated with poor CD19-directed CAR-T...
A GPRC5D-targeted CAR T-cell therapy led to a 71% response rate in patients with heavily pretreated multiple myeloma...
CD19-directed CAR T-cells led to a complete remission in around half of patients with relapsed/refractory CNS lymphoma.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
670 Madison Ave.
Manalapan, NJ 07726